top of page

Biotangents lead investor achieves record year

28 January 2020

 
John McNicol, founder and director of Kelvin Capital (left), with Alan Hale CEO of Biotangents (right)
John McNicol, founder and director of Kelvin Capital (left), with Alan Hale CEO of Biotangents (right)

Biotangents’ lead investors, Kelvin Capital, delivered a record level of activity in 2019. The syndicate’s total investments in 2018 were £10.5m and rose by 19% to £12.5m in 2019. These new heights in activity have been partially driven by an increase in membership from Europe and Asia, which has grown their total to 250 members, a 20% increase since 2018.


The 2019 record breaking year includes Kelvin’s £1.5m investment, alongside the Scottish Investment Bank, in Biotangents.


Since its foundation in 2009, the group has secured nearly £35m in investment for its portfolio companies and is currently managed by John McNicol and Angus Hay.


John McNicol stated: “In the last twelve months we have seen a series of important milestones being achieved by our portfolio companies.


A key part of our success is not just investing money but bringing in highly experienced industry specialists from our membership and vast network, who work with the portfolio companies to support and drive their growth ambitions.


“This brings even greater value to the businesses which will in turn benefit our investors.”

bottom of page